ACLX Arcellx
- 52.240
- +1.790+3.55%
Arcellx News
Arcellx Initiated at Overweight by Piper Sandler
Arcellx Initiated at Overweight by Piper Sandler
Arcellx (ACLX.US) was first covered by Piper Sandler, which gave it an increase rating, with a target price of $70.00.
Arcellx (ACLX.US) was first covered by Piper Sandler, which gave it an increase rating, with a target price of $70.00.
Piper Sandler Initiates Coverage On Arcellx With Overweight Rating, Announces Price Target of $70
Piper Sandler analyst Biren Amin initiates coverage on Arcellx (NASDAQ:ACLX) with a Overweight rating and announces Price Target of $70.
Optimistic Outlook for Arcellx Inc's Anito-cel With Strong Clinical Prospects and Strategic Partnerships
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Insider Sale: CFO Michelle Gilson Sells Shares of Arcellx Inc (ACLX)
Gilead (GILD.US) /ArcellX's Next-Generation BCMA CAR-T Launches Phase III Clinical Trial
Gilead (GILD.US) and ArcellX registered a phase III clinical trial of Anitocabtagene Autoleucel for the treatment of recurrent or refractory multiple myeloma on the ClinicalTrials.gov website.
Arcellx Is Maintained at Buy by Stifel
Arcellx Is Maintained at Buy by Stifel
Stifel: Maintaining the Arcellx (ACLX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $82.00 to $83.00.
Stifel: Maintaining the Arcellx (ACLX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $82.00 to $83.00.
Stifel Maintains Buy on Arcellx, Raises Price Target to $83
Stifel analyst Benjamin Burnett maintains Arcellx (NASDAQ:ACLX) with a Buy and raises the price target from $82 to $83.
Truist Financial Reaffirms Their Buy Rating on Arcellx Inc (ACLX)
Analyst Expectations For Arcellx's Future
During the last three months, 14 analysts shared their evaluations of Arcellx (NASDAQ:ACLX), revealing diverse outlooks from bullish to bearish.The following table summarizes their recent ratings, she
Arcellx Initiated at Outperform by Evercore ISI Group
Arcellx Initiated at Outperform by Evercore ISI Group
Arcellx (ACLX.US) was first covered by Evercore ISI Group, which gave it an superior market rating, with a target price of $85.00.
Arcellx (ACLX.US) was first covered by Evercore ISI Group, which gave it an superior market rating, with a target price of $85.00.
Evercore ISI Group Initiates Coverage On Arcellx With Outperform Rating, Announces Price Target of $85
Evercore ISI Group analyst Cory Kasimov initiates coverage on Arcellx (NASDAQ:ACLX) with a Outperform rating and announces Price Target of $85.
Buy Rating for Arcellx Inc. on Promising CAR-T Cell Therapy Trials and Strategic Market Positioning
Arcellx Price Target Cut to $80.00/Share From $82.00 by HC Wainwright & Co.
Arcellx Price Target Cut to $80.00/Share From $82.00 by HC Wainwright & Co.
Arcellx Is Maintained at Buy by HC Wainwright & Co.
Arcellx Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Arcellx, Lowers Price Target to $80
HC Wainwright & Co. analyst Emily Bodnar maintains Arcellx (NASDAQ:ACLX) with a Buy and lowers the price target from $82 to $80.
Buy Rating Affirmed for Arcellx Inc. Amidst Promising Trial Progress and Strategic Partnerships
Analysis
Price Target
No Data
